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ABSTRACT 
Hair is an important component of the body derived from ectoderm of skin. Keratin is the main component of hair fibers. Hair has great psycho-social 
significance for persons. The average growth rate in a normal scalp is 0.41 mm per day but lower growth rate is observed among aged persons and 
chronic disease persons. Hair loss is a most common problem among men and women of all age groups and it is a socially and psychologically 
distressing also. Its severity varies from a small bare patch to a more diffuse and obvious pattern. Diffuse hair loss may occur at any age and gender. It 
affects the whole scalp. Management of hair fall is extremely complex. Treatments for the various forms are available but alopecia has limited 
success. As a general rule, it is easier to maintain remaining hair than it is to re-grow; however, the success rate is very less with unwanted adverse 
effects. There are claims that poly herbal formulations are giving promising results. So, a poly herbal formulation ‘Hairbac’ tablet and oil, is evaluated 
for its safety and efficacy in diffuse hair loss. The subjective parameters used for assessment were Hair Texture, Hair Density/cm sq area and Hair 
Loss. The beneficial effects of Hairbac Tablets and Oil assessed in the context of hair texture, density /1cm
2 and hair loss among females suffering 
with diffuse hair fall showed highly significant improvement without any adverse effects assessed by the respondents. 
Keywords: Diffuse hair loss, Hair Texture, Hair Density, Hairbac tablet, Hairbac oil. 
 
INTRODUCTION 
Hair is a primary characteristic of mammals. Hair is an 
important component of the body derived from ectoderm 
of  skin.  It  is  protective  appendage  on  the  body  and 
considered  necessary  structure  of  the  integument  along 
with sebaceous glands, sweat glands and nails. Hair gives 
physical protection. It exerts a range of functions such as 
sensory  activity  and  thermoregulation.  It  influences  the 
social  life  and  social  interactions
1.  Keratin  is  the  main 
component  of  hair  fibers.  Hair  has  great  psycho-social 
significance  for  persons.  The  average  growth  rate  in  a 
normal scalp is 0.41 mm per day
2 but lower growth rate is 
observed  among  aged  persons  and  chronic  disease 
persons. Each scalp hair grows in three cyclic phases viz. 
Anagen (growth), catagen (involution) and telogen (rest)
3. 
The  anagen  phase  may  be  short  as  2-6  years  and 
approximately 80  % of hair follicles are  present in this 
phase.  The  remaining  percentage  of  hair  follicles  is 
present in catagen and in telogen phase. The hair growth 
activities  increases  in  catagen  phase  with  span  of  2-3 
weeks and moves to telogen phase i.e. resting state phase, 
lasts for 2-3 months. It is reported that in general 100-150 
hairs at random are shed every day
4. Hair loss is a most 
common  problem  among  men  and  women  of  all  age 
groups and it is a socially and psychologically distressing 
also. Its severity varies from a small bare patch to a more 
diffuse and obvious pattern. Diffuse hair loss may occur 
at any age and gender. It affects the whole scalp. Benign 
hair loss have marked deleterious effects on body-image, 
self  esteem  and  psychology  of  human  being.  The  most 
widespread form of hair loss is baldness affecting both the 
genders. Affected proportion of men by this morbidity is 
50 % by the age of 50 years and it increases by 80 % as 
age increased up to 80 %. 
 
Causes of Hair Fall  
The  causes  of  Hair  loss  is  multiple  faceted.  The 
commonest  are  cornrows,  Trichotillomania,  traumas, 
severe  stress,  Child  birth,  use  of  fertility-stimulating 
drugs,  fungus  infections,  Hypothyroidism,  sebaceous 
cysts,  certain  hereditary  disorders  and  short  anagen 
syndrome etc. The diagnosis of hair disorders is complex. 
Diagnostic techniques include clinical examination such 
as scalp condition; hair loss pattern; length and diameter 
of  hair  fibers;  one-minute  combing  test;  clipping, 
plucking  and  microscopic  examination  of  hair  fibers; 
scrapings of scalp scales for microbial culture and scalp-
punch  biopsy.  Other  laboratory  tests  such  as  complete 
blood count, ferritin measurement and thyroid screening 
may  be  helpful.  Management  of  hair  fall  is  extremely 
complex. Treatments for the various forms are available 
for alopecia but have limited success. As a general rule, it 
is easier to maintain remaining hair than it is to re-grow; 
however,  the  success  rate  is  very  less  with  unwanted 
adverse effects. There are new technologies in cosmetic 
transplant  surgery  and  hair  replacement  systems  are 
available and that can be completely undetectable. There 
are  claims  that  poly  herbal  formulations  are  giving Ranjan C. Rawal et al / Int. J. Res. Ayurveda Pharm. 4(4), Jul – Aug 2013 
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promising results. So, a poly herbal formulation ‘Hairbac’ 
tablet and oil, is evaluated for its safety and efficacy in 
diffuse hair loss. 
 
Drug Review 
Each Hairbac tablet contains: Amla (Emblica officinalis) - 
250 mg, Giloy (Tinospora cordifolia) -100 mg, Bhringraj 
(Eclipta alba) -50 mg, Anant mool (Hemidesmus indicus) 
-50 mg, Mulethi (Glycyrrhiza glabra) -50 mg, triturated 
and  Processed  with  the  extracts  of  Bhumi  Amla 
(Phyllanthus niruri), Safed Chandana ( Santalum album) 
and Spirulina (Blue green algae). The given Dosage is 2 
Tablets twice a day for 3 months. Each 100 ml Hairbac oil 
contains Sesame Oil - 50 ml, Groundnut oil - 40 ml, Olive 
Oil - 10 ml, Extracts derived from 10 g. each of Neela 
Patra  (Indigofera  tinctoria),  Bhringaraja  (Eclipta  alba), 
Brahmi  (Bacopa  monnieri),  Amla  (Emblica  officinalis), 
Jatamansi (Nardostachys jatamansi). It is advised to use 
Hairbac Oil by messaging the scalp hair.   
 
MATERIAL AND METHODS 
To evaluate the effect of Hairbac Oil and Hairbac Tablet 
in the management of diffuse hair loss; an open clinical 
study  was  planned  and  conducted  at  V.S.  Hospital, 
Ahmedabad  and  Gujarat,  India.  The  same  is  being 
approved by the Departmental Drug Research Committee 
vide  letter  No.  VS/DERMA/DDRC/2012-13/002  Dated 
05–01-2012  as  an  open  clinical  trial  on  phase  IV  post 
marketing surveillance study. 
 
Plan of Study 
Female patients who were suffering with diffuse hair loss 
visiting to the skin OPD of V.S. Hospital, Ahmedabad, 
Gujarat, India were registered in the study based on the 
following inclusive and exclusive criteria: 
 
Inclusion Criteria 
·  Female patients, whose age is more than 18 years; 
·  Patients; who are willing to give written, signed and 
dated informed consent to participate in the study. 
·  Patients who are clinically diagnosed for diffuse hair 
loss were included in this study. 
 
Exclusion Criteria 
The excusing criteria includes  
·  Pregnant  or  breastfeeding  or  planning  to  become 
pregnant during the study period,  
·  Known  case  of  Hypersensitivity  to  Investigational 
drug content,  
·  Patient using any other treatment for this indication at 
the same time  
·  Received any other investigational medicinal therapy 
within 30 days and topical therapy within 7 days prior 
to screening  
·  Patient  suffering  from  any  active  general  illness  or 
have History of any general illness 
 
Study Groups and Duration of study 
A group of 40 female patients enrolled in this study and 
out  of  which  37  were  completed  the  study.  The  total 
period  of  study  was  3  months  with  3  follow-ups  at  1 
month each as interval.  The study was conducted from 
February 2012 to May 2012. 
 
Clinical Study 
The information related to demographic details, history of 
present illness, medical history and personal history was 
recorded  in  prepared  case  sheet  for  this  purpose.  The 
subjective parameters used for assessment are as follows.  
 
Hair Examination 
·  Hair  Texture:  Examined  by  simple  method  of 
touching the patient’s Hair. 
·  Hair Density/cm sq area: Examined at a fixed site of 
scalp with Trichoscope. 
·  Hair  Loss:  Counted  after  constant  combing  of 
patient’s hair for one minute with the same comb.  
 
The Grading of assessment is as follows: 
The Grading of assessment – Hair Texture, Density and 
Loss (Table 1) 
Laboratory parameters: Serum Hb. %g, serum ferritin,  
Evaluation of treatment  
This is done by subjective and objective analogue scale 
which is given below. 
Evaluation  of  treatment  on  symptoms  Hair  Texture, 
Density and Loss – The Analogue Scores (Table 2) 
The  adverse  effect  of  infection  was  recorded  for  all 
eligible subjects.   
 
Statistical Analysis 
The  quantitative  and  analogue  scale  variables  were 
presented  in  the  form  of  mean  and  standard  deviation 
along with range. The paired t-test was applied to find out 
the significant difference in the mean values of analogue 
scale from base line to different follow- ups i.e. at one, 
two  and  three  months  intervals.  The  qualitative  and 
categorical  variables  were  presented  in  number  and 
percentage.  The  16  .0  version  of  SPSS  (Statistical 
Package  for  Social  Science)  developed  by  IBM 
(International Business Machine), USA, was used for data 
analysis.  
 
RESULTS 
Baseline characteristics of the study subjects (N=37) 
The  mean  age  of  patients  was  38.76  years  and  the 
standard deviation was 13.06. The range was 18- 60. The 
mean of duration of illness in years was 2.29 and standard 
deviation was 1.27 while range was 0.5-6.0. The mean of 
hemoglobin was 11.97 and standard deviation was 1.22 
while the range for this parameter was 9.12-14.40. The 
mean of serum ferretin was 27.82 and standard deviation 
was 41.36. The range of it was 1.87-226.26. The standard 
deviation  of  abnormal  serum  ferretin  was  9  (24.30  %). 
The hair textures are grouped in three different group’s 
viz. Good, moderate and rough. 5 patients have good hair 
texture (13.60 %). The moderate texture was present with 
16  patients  (43.20  %)  while  16  (43.20  %)  patients  are 
having rough hair texture. The mean hair density was 4.22 
and the standard deviation was 47.55.  The range is 16-
340. The mean hair loss (combing for one minute) was 
108.47 and the standard deviation was 24.31.  The range 
is 55-170. (Table 3) Ranjan C. Rawal et al / Int. J. Res. Ayurveda Pharm. 4(4), Jul – Aug 2013 
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Subjective  improvement  among  hair  examinations  at 
different follow ups (N=37) 
 
 
Table 1: Grading of assessment – Hair Texture, Density and Loss 
 
Observation  Description  Score 
Hair Texture: 
No improvement  Same Texture  0 
Poor  improvement  A little smoother  1 
Fair improvement  Greatly smoother  2 
Excellent improvement  Smooth and shiny  3 
Hair Density/cm sq area: 
No improvement  Same  0 
Poor  improvement  10-15  1 
Fair improvement  15-20  2 
Excellent improvement  20-25  3 
Hair Loss : 
No improvement  Same  0 
Poor  improvement  >150  1 
Fair improvement  100-150  2 
Excellent improvement  80-100  3 
 
Table 2: Evaluation of treatment on symptoms Hair Texture, Density and Loss – The Analogue Scores 
 
Analogue Scale Scores  Description  Improvement 
0  No improvement  <25 % reduction 
1  Poor improvement  25 to 49 % reduction 
2  Fair improvement  50 to 74 % reduction 
3  Excellent improvement  >75 % reduction 
 
Table 3: Baseline characteristics of the study subjects (N=37) 
 
Parameter  Mean  S.D.  Range 
Age (in years)  38.76  13.06  18-60 
Duration of illness (in years)  2.29  1.27  0.5-6.0 
Hemoglobin  11.97  1.22  9.12-14.40 
Serum Ferretin  27.82  41.36  1.87-226.26 
Abnormal Serum Ferretin  9 (24.3 %) 
Hair Texture  Good 
5(13.6 %) 
Moderate 
16 (43.2 %) 
Rough 
16 (43.2 %) 
Hair Density /1 cm2  4.22  47.55  16-340 
Hair loss (combing for one minute)  108.47  24.31  55-170 
 
Table 4: Subjective improvement among hair examinations at different follow ups (N=37) 
 
Hair examination  1 Month  2 Months  3 Months 
Hair Texture       
Poor improvement  30 (81.1)  12 (32.4)  1 (2.7) 
Fair improvement  7 (18.9)  24 (64.9)  24 (64.9) 
Excellent improvement    1 (2.7)  12 (32.4) 
Mean  1.19  1.68  2.30 
S.D.  0.40  0.58  0.52 
t-value  18.22  17.58  26.88 
p-value  <0.001  <0.001  <0.001 
Density /1cm
2 
No improvement  10 (27.1)     
Poor improvement  18 (48.5)  17 (45.9)  6 (16.2) 
Fair improvement  9 (24.3)  18 (48.6)  15 (40.6) 
Excellent improvement    2 (5.4)  16 (43.2) 
Mean  0.97  1.60  2.27 
S.D.  0.73  0.60  0.73 
t-value  8.15  16.19  18.86 
p-value  <0.001  <0.001  <0.001 
Hair Loss 
No improvement  1 (2.7)     
Poor improvement  18 (48.6)  9 (24.3)  2 (5.4) 
Fair improvement  18 (48.6)  25 (67.6)  22 (59.5) 
Excellent improvement    3 (8.1)  13 (35.1) 
Mean  1.46  1.84  2.27 
S.D.  0.56  0.55  0.65 
t-value  15.92  20.20  21.19 
p-value  <0.001  <0.001  <0.001 
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Table 5: Objective improvement among hair examinations at different follow ups (N=37) 
 
Hair examination  1 Month  2 Months  3 Months 
Hair Texture 
Poor improvement  30 (81.1)  13 (35.1)  3 (8.1) 
Fair improvement  7 (18.9)  23 (62.2)  21 (50.8) 
Excellent improvement    1 (2.7)  13 (35.1) 
Mean  1.19  1.68  2.27 
S.D.  0.40  0.53  0.61 
t-value  18.22  19.24  22.72 
p-value  <0.001  <0.001  <0.001 
Density /1cm2 
No improvement  9 (24.3)  1 (2.7)   
Poor improvement  18 (48.6)  13 (35.1)  7 (18.9) 
Fair improvement  10 (27.0)  21 (56.8)  20 (54.1) 
Excellent improvement    2 (5.4)  10 (27.0) 
Mean  1.03  0.73  2.08 
S.D.  1.65  0.63  0.68 
t-value  8.61  15.84  18.55 
p-value  <0.001  <0.001  <0.001 
Hair Loss 
No improvement  1 (2.8)     
Poor improvement  18 (48.6)  8 (21.6)  3 (.1) 
Fair improvement  18 (48.6)  25 (67.6)  19 (51.4) 
Excellent improvement    4 (10.8)  15 (40.5) 
Mean  1.46  1.89  2.32 
S.D.  0.56  0.57  0.63 
t-value  15.92  20.30  22.59 
p-value  <0.001  <0.001  <0.001 
 
Table 6: Final evaluation of Hairbac tablet and Hairbac oil after 3 Months among diffused hair loss female patients (N=37) 
 
Improvement  Assessed by  c c c c2 (p-value) 
Subjective  Objective 
Poor  6 (16.22)  7 (18.92)   
0.284(0.87)  Fair  19 (51.35)  20 (54.05) 
Excellent  12 (32.43)  10 (27.03) 
Score Mean ± S.D.  15.65 ± 3.22  15.60 ± 3.03 
Range  9-22  10-23 
 
 
 
 
Figure 1: Final Evaluation of Hairbac Tablet and Hairbac Oil after 3 Months treatment among diffused Hair Loss in female patients 
The above graph shows that Hairbac tablet and oil showed subjective improvement in 83.78 % of cases, whereas Hairbac tablet and oil have shown 
objective improvement in 81.08  % of cases. This includes fair and excellent results. 
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The poor improvements in the hair texture were observed 
in 30 (81.10 %) patients after one month, in 12 (32.40 %) 
patients after two months and in 1 (2.7 %) patient after 
three months. The fair improvements were observed in 7 
(18.9 %), 24 (64.90 %) and 24 (64.90 %) patients after 1, 
2 and 3 months respectively. The excellent improvement 
was observed in only 1 (2.7 %) and 12 (32.40 %) patients 
after  2  and  3  months  respectively.  The  mean  for 
improvements after 1, 2 and 3 months were 1.19, 1.68 and 
2.30 respectively. The standard deviation for one month 
was 0.40, two months was 0.58 and 2.30 for three months. 
The t-value for one month, two months and three months 
are 18.22, 17.58 and 26.88 respectively. The improvement 
in density/ 1 cm square was as described. There were 10 
(27.10 %) patients who observed no improvement in hair 
density  after  one  month.  There  were  18  (48.50  %),  17 
(45.90  %)  and  6  (16.20)  patients  were  shown  poor 
improvement  after  1,  2  and  three  months  respectively. 
The  fair  improvement  was  shown  in  9  (24.30  %),  18 
(48.60 %) and 15 (40.60 %) patients after one, two and 
three  months  respectively.  The  excellent  improvement 
was shown in 2 (5.4 %) and 16 (43.20 %) after two and 
three  months  respectively.  The  mean  of  density 
improvement was 0.97 for one month, 1.60 for two month 
and 2.27 for three months. The standard deviation for one 
month was 0.73, 0.60 for two months and 0.73 for three 
months. The t –value for this were 8.15, 16.19 and 18.86. 
In hair loss no improvement is shown in only one patient 
(2.7%).  The  poor  improvement  was  shown  in  18  (48.6 
%), 9 (24.3 %) and 2 (5.4 %) patients after one, two and 
three  months  respectively  while  fair  improvement  was 
shown  in  18  (48.6  %),  25  (67.6  %)  and  22  (59.50  %) 
patients after one, two and three months respectively. The 
excellent improvement was shown only in 3 (8.1 %) and 
13  (35.10  %)  patients  after  two  and  three  months 
respectively. The mean for improvement in hair loss after 
one  month was 1.46, 1.84 and 2.27 after  one, two  and 
three months respectively. The standard deviation for one, 
two and three months are 0.56, 0.55 and 0.65. t- Value for 
one month, two months and three months are 15.92, 20.20 
and 21.19 respectively. (Table 4) 
Objective  improvement  among  hair  examinations  at 
different follow ups (N=37) 
The hair texture was improved in following manner. Poor 
improvement was observed in 30 (81.10 %) patients after 
one month, 13 (35.10 %) showed again poor improvement 
after two month and only 3 (8.10 %) patients showed poor 
improvement after three  months. Fair improvement was 
observed in 7 (18.90 %), 23 (62.20 %) and 21 (50.80 %) 
patients  after  one,  two  and  three  months  respectively 
while excellent improvement was observed in only 1 (2.7 
%) and 13 (35.10 %) patients after two and three months 
respectively. The mean score was 1.9 for one month, 1.68 
for  two  month  and  2.27  for  three  months.  Standard 
deviations were 0.40, 0.52 and 0.61 for one, two and three 
months respectively. Paired t--value for one month, two 
months  and  three  months  are  18.22,  19.24  and  22.72 
which  shows  very  highly  significant  improvement.  The 
density of hair in per cm square was also observed. The 
values  are  mentioned  here.  No  improvement  was 
observed  in  9(24.3)  %),  1(2.7%)  patients  after  one  and 
two  months  respectively.  Poor  improvement  was 
observed in 18 (48.6 %), 13 (35.1 %) and 7 (18.9 %) after 
one, two and three months respectively. Fair improvement 
was observed in only 10 (27 %), 21 (56.8 %) and 20 (54.1 
%)  patients  after  one,  two  and  three  months  while 
excellent improvement was observed in only 2 (5.4 %) 
and  10  (27  %)  patients  after  two  and  three  months 
respectively.  The  mean  for  one  month,  two  month  and 
three  months  are  1.03,  0.73  and  2.08  respectively.  The 
standard deviations are 1.65, 0.63 and 0.68 after one, two 
and  three  months  respectively.  T-value  for  one  month, 
two months and three months are 8.61, 15.84 and 18.55 
respectively.  The  improvement  in  hair  loss  was  also 
observed. Only 1 (2.8%) patient showed no  improvement 
in  hair  loss  after  one  month.  Poor  improvement  was 
observed  in  18  (48.6  %),  8  (21.6  %)  and  3  (0.1  %) 
patients after one, two and three months respectively. Fair 
improvement was observed in 18 (48.6 %), 25 (67.6 %), 
19  (51.4  %)  patients  after  one,  two  and  three  months 
respectively  while  excellent  improvement  was  observed 
in only 4 (10.8 %) and 15 (40.5 %) patients after two and 
three  months  respectively.  The  mean  for  one,  two  and 
three  months  are  1.46,  1.89  and  2.32  respectively.  The 
standard deviations were 0.56, 0.57 and 0.63. T- Value for 
one, two and three months was 15.92, 20.30 and 22.59 
respectively. (Table 5) 
Final evaluation of Hairbac tablet and Hairbac oil after 3 
Months among diffused hair loss female patients (N=37) 
The final evaluation  of the effect  of  Hairbac tablet and 
Hairbacoil after three months of treatment assessed by the 
study subjects and objective evaluation by the treatment 
physician as shown in Table 4. The mean subjective score 
was  15.65  with  standard  deviation  3.22  and  objective 
score mean was 15.60 with standard deviation 3.03. There 
was  no  significant  difference  in  the  subjective  and 
objective  score  evaluation.  The  excellent  improvement 
was assessed by 32.43 % subject as compared to 27.13 % 
by  the  physician.  No  significant  association  was  found 
between  improvement  level  and  assessed  persons 
c2=0.284,  p=0.87.  The  comparative  evaluation  of 
subjective  and  objective  assessment  was  also  shown  in 
Figure 1 through bar diagram. (Table 6) 
 
DISCUSSION 
The  treatment  and  management  of  diffuse  hair  loss  in 
both  the  sexes  among  all  age  group  was  extremely 
complex.  Hormone  therapy,  Use  of  e-reductase 
inhibitions, synthetic drugs, minoxidil, new technologies 
in  cosmetics  transplant  surgery  and  hair  replacement 
systems  are  available  for  the  treatment  of  hair  loss/fall 
with  some  adverse  effects.  The  result  of  present  study 
with  poly-herbal  formulation  -  Hairbac  tablet  and 
Hairbacoil had shown that this combination is beneficial 
in the management of diffuse hair loss. In the context of 
hair texture 32.4 % respondents were found themselves as 
excellent  improvement  and  35.1  %  respondents  were 
assessed  by  the  treating  physicians  as  excellent 
improvement. In the density / 1 cm
2 43.2 % respondents 
were assessed as subjective and 27.0 % as objective for 
excellent improvement. 35.1 % respondents were assessed 
as excellent improvement on subjective basis and 40.5 % 
as objective basis in context of hair loss. It is observed Ranjan C. Rawal et al / Int. J. Res. Ayurveda Pharm. 4(4), Jul – Aug 2013 
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that  in  overall  one  third  subjects  found  an  excellent 
improvement. 
 
Probable Mode of action of trial drug Hairbac tablet 
and Hairbac oil 
As mentioned earlier Each Hairbac tablet contains various 
herbs and Hairbac oil contains various oils and herbs at 
different  concentration.  The  synergetic  effect  of 
combination  of  these  ingredients  is  resulting  in  to 
different  pharmacological  actions.  Various  studies 
conducted on these herbs has proven that these herbs have 
immunosuppressive,  antioxidant,  immune-booster,  anti-
bacterial,  anti-inflammatory  and  anti-allergic  properties, 
rejuvenative, alterative, demulcent, diaphoretic, diuretic, 
blood purifier antiseptic, demulcent actions.
5-10. 
 
CONCLUSION 
The present study concludes that Hairbac tablet and oil is 
a  very  effective  and  absolutely  safe  treatment  in  the 
management of diffused hair loss. The beneficial effects 
of Hairbac Tablets and Oil assessed in the context of hair 
texture,  density  /  1  cm
2  and  hair  loss  among  females 
suffering with diffuse hair fall showed highly significant 
improvement without any adverse effects assessed by the 
respondents. Therefore, it can be concluded that Hairbac 
Tablets  and  Oil  is  safe  and  cases  effective  treatment 
among diffuse hair loss.  
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